Drugs / MOC31PE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01061645 | Sep 2010 → Feb 2012 | carcinoma | Oslo University Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02219893 | Aug 2014 → Dec 2016 | colorectal neoplasm | Oslo University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOC31PE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02219893 ↗ |
| Action | Inhibit | “The effector moieties of the IT used here, the Pseudomonas exotoxin A (PE), inhibits protein synthesis in eukaryotic cells by catalytic inactivation (ribosylation) of...” NCT01061645 ↗ |
| Modality | Other / unclassified | “MOC31PE is an immunotoxin” NCT02219893 ↗ |
| Target | EPCAM | “Epithelial cell adhesion molecule binding agent” CHEMBL2109265 ↗ |